82/100
✓ Peer-reviewed
alzhub usefulness score 82 out of 100.
·
Neurology
·
2020-07-01
The incidence rate of dementia in Europe and North America has declined by 13% per decade over the past 25 years, consistently across studies. 2 key findings →
Design: cohort study
Participants: 49,202
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
White matter hyperintensities are associated with an increased risk of all-dementia and Alzheimer's disease in the general population. 3 key findings →
Design: meta-analysis
Participants: 3,913
Evidence: high
Full summary, score breakdown and related studies →
Original source
73/100
✓ Peer-reviewed
alzhub usefulness score 73 out of 100.
·
BMJ
·
2025-01-08
The average life expectancy of people with dementia at time of diagnosis ranged from 5.7 years at age 65 to 2.2 at age 85 in men and from 8.0 to 4.5, respectively, in women. 5 key findings →
Design: meta-analysis
Participants: 5,553,960
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
We conducted a meta-analysis of the conflicting epidemiologic evidence on the association between midlife body mass index (BMI) and dementia. 4 key findings →
Design: meta-analysis
Participants: 19
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
71/100
✓ Peer-reviewed
alzhub usefulness score 71 out of 100.
·
PloS one
·
2019-07-29
The APOE-ε4 allele has long been associated with increased risks of Alzheimer's disease and mortality, but the effect of the less prevalent APOE-ε2 allele on diseases in the elderly and survival remains elusive. 4 key findings →
Design: cohort study
Participants: 38,537
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Alzheimer's disease is one of the most heritable diseases in elderly people and the most common type of dementia. 4 key findings →
Design: cohort study
Participants: 926
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
67/100
✓ Peer-reviewed
alzhub usefulness score 67 out of 100.
·
Circulation
·
2017-06-06
Cerebral hypoperfusion has previously been associated with mild cognitive impairment and dementia in various cross-sectional studies, but whether hypoperfusion precedes neurodegeneration is unknown. 4 key findings →
Design: cross-sectional
Participants: 4,759
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
To systematically review the literature for dementia prediction models for use in the general population and externally validate their performance in a head-to-head comparison. 4 key findings →
Participants: 867
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
66/100
✓ Peer-reviewed
alzhub usefulness score 66 out of 100.
·
JAMA neurology
·
2018-10-01
Retinal structures may serve as a biomarker for dementia, but longitudinal studies examining this link are lacking. 4 key findings →
Design: longitudinal study
Participants: 5,065
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
65/100
✓ Peer-reviewed
alzhub usefulness score 65 out of 100.
·
JAMA neurology
·
2015-11-01
Atrial fibrillation (AF) has been suggested as a risk factor for dementia since it may lead to chronic cerebral hypoperfusion and stroke. 4 key findings →
Design: longitudinal study
Participants: 6,514
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
63/100
✓ Peer-reviewed
alzhub usefulness score 63 out of 100.
·
PLoS medicine
·
2017-03-21
Overall, cumulative incidence was uniformly higher in NACC than in the population-based cohorts. 3 key findings →
Participants: 5,073
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
62/100
✓ Peer-reviewed
alzhub usefulness score 62 out of 100.
·
JAMA neurology
·
2016-08-01
Microbleed prevalence was 15.3% (median [interquartile range] count, 1 [1-88]). 5 key findings →
Participants: 4,841
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
61/100
✓ Peer-reviewed
alzhub usefulness score 61 out of 100.
·
Neurology
·
2019-07-31
During a mean follow-up of 12.1 years, 1,520 individuals developed dementia, 1,194 of whom had AD. 4 key findings →
Participants: 12,305
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
60/100
✓ Peer-reviewed
alzhub usefulness score 60 out of 100.
·
Neurology
·
2016-09-16
Analyses were performed within the Rotterdam Study (baseline 1997), a prospective, population-based cohort. 4 key findings →
Participants: 9,446
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
60/100
✓ Peer-reviewed
alzhub usefulness score 60 out of 100.
·
Neurology
·
2017-03-29
From 2000 to 2002, we assessed parental history of dementia in participants without dementia of the Rotterdam Study. 4 key findings →
Participants: 2,087
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
58/100
✓ Peer-reviewed
alzhub usefulness score 58 out of 100.
·
PLoS medicine
·
2016-10-11
Orthostatic hypotension (OH) is a common cause of transient cerebral hypoperfusion in the population. 4 key findings →
Participants: 6,204
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
58/100
✓ Peer-reviewed
alzhub usefulness score 58 out of 100.
·
NeuroImage
·
2018-05-18
Total hippocampal volume has been consistently linked to cognitive function and dementia. 4 key findings →
Participants: 5,035
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Vitamin D has gained interest as a potentially modifiable risk factor for dementia because of its putative neuroprotective effects. 4 key findings →
Design: longitudinal study
Participants: 6,220
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
Cerebral vasoreactivity (CVR) is a key factor in maintenance of continuous cerebral perfusion and a marker of (micro)vascular damage. 4 key findings →
Design: longitudinal study
Participants: 1,629
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
Identification of individuals at high risk of dementia is essential for development of prevention strategies, but reliable tools are lacking for risk stratification in the population. 4 key findings →
Participants: 181
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Late-life depressive symptoms have been extensively studied for their relationship with incident dementia, but have been typically assessed at a single timepoint. 4 key findings →
Participants: 3,325
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
55/100
✓ Peer-reviewed
alzhub usefulness score 55 out of 100.
·
JAMA neurology
·
2017-12-01
Cognitive dysfunction is a common feature among patients with parkinsonism, including Parkinson disease (PD). 4 key findings →
Participants: 7,386
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
55/100
✓ Peer-reviewed
alzhub usefulness score 55 out of 100.
·
Neurology
·
2017-09-20
Within the prospective population-based Rotterdam Study, we measured serum magnesium levels in 9,569 participants, free from dementia at baseline (1997-2008). 4 key findings →
Participants: 9,569
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
54/100
✓ Peer-reviewed
alzhub usefulness score 54 out of 100.
·
GeroScience
·
2023-08-03
Neurofilament light chain (NfL) is a promising biomarker for risk stratification and disease monitoring of dementia, but its utility in the preclinical disease stage remains uncertain. 4 key findings →
Participants: 975
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Within the prospective population-based Rotterdam Study, we studied lifetime risk of dementia, stroke and parkinsonism between 1990 and 2016. 4 key findings →
Participants: 102
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 27,380 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.